These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 6389477)
41. [Ergoferon liquid dosage form--efficacious and safe treatment for childhood acute respiratory infections. Interim outcomes of a multi-center, randomized, double-blind, placebo-controlled clinical trial]. Geppe NA; Kondiurina EG; Galustian AN; Pak TE; Bal'tserovich NB; Zhiglinskaia OV; Kamaev AV; Lazareva SG; Laléko SL; Mel'nikova IM; Perminova OA; Sabitov AU Antibiot Khimioter; 2014; 59(5-6):6-14. PubMed ID: 25552038 [TBL] [Abstract][Full Text] [Related]
42. Tolerance and pharmacokinetics of oral fendiline. Weyhenmeyer R; Fenzl E; Apecechea M; Rehm KD; Dyde CJ; Johnson KJ; Friedel R Arzneimittelforschung; 1987 Jan; 37(1):58-62. PubMed ID: 3566858 [TBL] [Abstract][Full Text] [Related]
43. An evaluation of pelvic tissue concentrations after oral administration of enoxacin. Bates SA; Elder MG J Antimicrob Chemother; 1988 Feb; 21 Suppl B():79-85. PubMed ID: 3162905 [TBL] [Abstract][Full Text] [Related]
44. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095 [TBL] [Abstract][Full Text] [Related]
45. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971 [TBL] [Abstract][Full Text] [Related]
46. Lack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers. Davy M; Bird N; Rost KL; Fuder H Chemotherapy; 1999; 45(6):491-5. PubMed ID: 10567780 [TBL] [Abstract][Full Text] [Related]
47. Diffusion of enoxacin into the cerebrospinal fluid in dogs with healthy meninges and with experimental meningitis. Tran Van Tho ; Armengaud A; Davet B J Antimicrob Chemother; 1984 Sep; 14 Suppl C():57-62. PubMed ID: 6594323 [TBL] [Abstract][Full Text] [Related]
48. Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects. Astruc B; Tarral A; Dostert P; Mariotti F; Fabbri L; Imbimbo BP Br J Clin Pharmacol; 2005 Apr; 59(4):405-14. PubMed ID: 15801935 [TBL] [Abstract][Full Text] [Related]
49. Mitoxantrone: a review of its use in multiple sclerosis. Scott LJ; Figgitt DP CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110 [TBL] [Abstract][Full Text] [Related]
51. Enoxacin for the treatment of urinary tract infection. Bailey RR; Peddie BA N Z Med J; 1985 Apr; 98(777):286-8. PubMed ID: 3857511 [TBL] [Abstract][Full Text] [Related]
52. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers. Lasseter K; Dilzer S; Jansat JM; Garcia Gil E; Caracta CF; Ortiz S Pulm Pharmacol Ther; 2012 Apr; 25(2):193-9. PubMed ID: 22366196 [TBL] [Abstract][Full Text] [Related]
53. The activity of enoxacin against clinical bacterial isolates in comparison with that of five other agents, and factors affecting that activity. Reeves DS; Bywater MJ; Holt HA J Antimicrob Chemother; 1984 Sep; 14 Suppl C():7-17. PubMed ID: 6594324 [TBL] [Abstract][Full Text] [Related]
55. A comparison of enoxacin and co-trimoxazole in the treatment of patients with complicated urinary tract infections. Cox CE J Antimicrob Chemother; 1988 Feb; 21 Suppl B():113-8. PubMed ID: 3258862 [TBL] [Abstract][Full Text] [Related]
56. Enoxacin treatment of urinary tract infections in elderly patients. Huttunen M; Kunnas K; Saloranta P J Antimicrob Chemother; 1988 Feb; 21 Suppl B():105-11. PubMed ID: 3162900 [TBL] [Abstract][Full Text] [Related]
57. Enoxacin in the treatment of lower respiratory tract infections. Philip-Joet F; Nourrit J; Frances Y; Arnaud A J Antimicrob Chemother; 1988 Feb; 21 Suppl B():125-9. PubMed ID: 3258863 [TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics and pharmacodynamics of setrobuvir, an orally administered hepatitis C virus non-nucleoside analogue inhibitor. Mallalieu NL; Rahimy MH; Crowley CA; Appleman JR; Smith PF; Freddo JL Clin Ther; 2014 Dec; 36(12):2047-2063.e3. PubMed ID: 25456558 [TBL] [Abstract][Full Text] [Related]
59. Effect of omeprazole on the pharmacokinetics of oral gemifloxacin in healthy volunteers. Allen A; Vousden M; Lewis A Chemotherapy; 1999; 45(6):496-503. PubMed ID: 10567781 [TBL] [Abstract][Full Text] [Related]
60. High-performance liquid chromatography and preliminary pharmacokinetics of enoxacin and its 4-oxo metabolite in human plasma, urine and saliva. Vree TB; Baars AM; Wijnands WJ J Chromatogr; 1985 Oct; 343(2):449-54. PubMed ID: 3864785 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]